Hørsholm, Denmark / San Diego, California — Santaris Pharma A/S, a privately held biopharmaceutical company announced a worldwide strategic alliance with Bristol-Myers Squibb (NYSE: BMY) to develop novel medicines using Santaris Pharma’s proprietary Locked Nucleic Acid (LNA) Drug Platform.

Under the terms of the agreement, Santaris Pharma will receive an upfront payment of $10 million, up to $90 million in potential milestone payments per product and funding of ongoing discovery and research activities. In addition, Santaris Pharma will be eligible to receive royalties on the worldwide sales of all medicines arising from the alliance.

About Santaris Pharma A/S

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States.

Please visit www.santaris.com for more information.